阿帕替尼聯(lián)合化療對(duì)晚期胃癌化療后進(jìn)展的療效及安全性觀察

宋濱　隋超

【摘要】 目的 分析阿帕替尼聯(lián)合化療對(duì)晚期胃癌化療后進(jìn)展的療效及安全性觀察。方法 98例晚期胃癌患者， 按隨機(jī)數(shù)字表法分為對(duì)照組和研究組， 每組49例。對(duì)照組給予伊立替康靜脈注射+替吉奧膠囊或靜脈注射紫杉醇+替吉奧膠囊， 研究組在對(duì)照組的基礎(chǔ)上結(jié)合阿帕替尼化療方案。比較兩組患者臨床療效、不良反應(yīng)發(fā)生情況、化療前后的腫瘤標(biāo)志物癌胚抗原（CEA）、糖類(lèi)抗原CA199（CA-199）水平。結(jié)果 研究組客觀緩解率（ORR）53.06%、疾病控制率（DCR）91.84%均高于對(duì)照組的32.65%、77.55%， 不良反應(yīng)發(fā)生率14.29%低于對(duì)照組的36.73%， 差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。化療后， 研究組患者CEA水平（5.18±1.11）ng/ml、CA-199水平（25.14±0.46）U/ml， 均低于對(duì)照組的（7.18±0.76）ng/ml、（35.13±0.55）U/ml， 差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 使用阿帕替尼聯(lián)合化療治療晚期胃癌患者， 其治療效果顯著， 不良反應(yīng)少， 安全性較高， 臨床上值得推廣使用。

【關(guān)鍵詞】 阿帕替尼;化療;晚期胃癌;治療療效;安全性

DOI：10.14163/j.cnki.11-5547/r.2020.31.041

Observation of the efficacy and safety of apatinib combined with chemotherapy on the progression of advanced gastric cancer after chemotherapy? ?SONG Bin， SUI Chao. Department of Surgical Oncology， Weifang Hospital of Traditional Chinese Medicine， Weifang 261031， China

【Abstract】 Objective? ?To analyze the efficacy and safety of apatinib combined with chemotherapy on the progression of advanced gastric cancer after chemotherapy. Methods? ?A total of 98 patients with advanced gastric cancer were divided into control group and research group according to random numerical table， with 49 cases in each group. The control group was treated with irinotecan intravenous injection + tigio capsule or intravenous paclitaxel + tigio capsule， and the research group was treated with apatinib chemotherapy regimen on the basis of the control group. The clinical efficacy， occurrence of adverse reactions， levels of carcinoembryonic antigen （CEA） and carbohydrate antigen CA199 （CA-199） before and after chemotherapy were compared between the two groups. Results? ?The objective remission rate （ORR） 53.06% and disease control rate （DCR） 91.84% of the research group were higher than 32.65% and 77.55% of the control group， and incidence of adverse reactions 14.29% was lower than 36.73% of the control group， and the difference was statistically significant （P<0.05）. After chemotherapy， CEA （5.18±1.11） ng/ml and CA-199 （25.14±0.46） U/ml of the research group were lower than （7.18±0.76） ng/ml and （35.13±0.55） U/ml of the control group， and the difference was statistically significant （P<0.05）. Conclusion? ?Apatinib combined with chemotherapy shows significant therapeutic effect on advanced gastric cancer patients with less adverse reactions and high safety. It is worthy of clinical promotion and application.

【Key words】 Apatinib; Chemotherapy; Advanced gastric cancer; Treatment efficacy; Safety